@save they may be selling anything above that 1630 fair dues, but Genting has made no such recovery all other counters have had a good run! Except Genting and still we have faith in the old far. Only saviour is TauRX and MHRA and not US as they won’t approve non US based pharmaceuticals unless they have huge presence in US. US by this means is not open market for sure just pretend.
According to Maybank IB Research, the share price weakness was more likely due to foreign selling from the weaker ringgit compared to the US dollar.
The research house added that since inflation in the United States has tapered down, and the ringgit is likely to recover against the dollar backed by the prospect of the Federal Reserve cutting the interest rate, it hopes the foreign selling will decrease.
“Our FX Research Team forecasts the US dollar/ringgit to recover to 4.600 by end-2024, and 4.500 by mid-2025 from 4.718 as at June 30, 2024.
Times have indeed changed since Trump's first term. The interest rate environment is much higher today, and maintaining high rates indefinitely is not sustainable. The Fed may have to balance between supporting the economy and keeping the dollar "strong".
Foreign fund nett buying Day 13 yesterday +64M, Local institution keep nett selling -84M. KLCI short term target 1630 seems broken, let see closing index if can maintain above 1630. Any successful breakout will bring KLCI towards 1680! Is Genting turn this round? Watch 4.85
September meeting. FDA wants us to combine both AA and Full Approval sessions into 1 meeting instead of 2 separate meetings. KNN how to do both of them within a 60 min meeting? I think better focus on AA liow as Full Approval seems like a long shot to me due to trial placebo issues.
Accelerated Approval. Its usually a 8 to 10 yrs temporary commercialisation Approval to sell the drug but need to do n complete another confirmatory trial within this duration. AA primarily deals with biomarkers like Tau reduction, NfL reduction, slowdown in brain shrinkage to gain quick temporary approval. For taurx's case, although our drug can totally halt cognition decline n even reverse back up (its a cure), our placebo arm was later found to be an active dose (a low dose MTC formula for blue pee discolouration). Hence using traditional full approval standards, i doubt FDA will give us full approval (didn't meet primary endpoints measurements when compared against placebo arm)
MAGA: Trump will make the US great again. With Resorts World New York City and Resorts World Las Vegas expected to see exponential growth, Genting Berhad could be headed to the moon!
@Riaz, unfortunately FDA is not our friend. The FDA officials (civil service) are usually more cozy with large pharma MNCs due to future job prospects at the private sector.
Indeed Genting is a big laggard. It needs a catalyst. It seems there are nobody willing to chase. When time comes like an earthquake it will catapult! Wait at the starting blocks. Anytime after Sept I say.
Uncertainties persist as investors worry that tech stocks will stumble after the US presidential election. Consider buying tech stocks after the election.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Riaz1954
1,350 posts
Posted by Riaz1954 > 2024-07-16 15:12 | Report Abuse
@save they may be selling anything above that 1630 fair dues, but Genting has made no such recovery all other counters have had a good run! Except Genting and still we have faith in the old far. Only saviour is TauRX and MHRA and not US as they won’t approve non US based pharmaceuticals unless they have huge presence in US. US by this means is not open market for sure just pretend.